New treatment being researched: Inspiritol—Today’s Press Release


Moderation Resource Albuquerque
FAIRFIELD, Conn., Oct. 25, 2021/PRNewswire/ -- Inspiritol, Inc., a virtual pharmaceutical start-up filed a response with the FDA as part of their Investigational New Drug Application process for Inspiritol, a novel treatment for COVID-19, Long-COVID, and ME/CFS (Myalgic encephalomyelitis/chronic fatigue). Inspiritol is a nebulized inhaled multi-mechanism medication designed to treat the major symptoms of respiratory distress with anti-oxidant, anti-inflammatory, and broad spectrum anti-viral and anti-bacterial properties. Inspiritol is comprised of both endogenously produced and naturally occurring, well tolerated biochemicals co-developed by Dr. John P. Salerno, MD with a practice in New York City and George E. Hoag, Ph.D. Inspiritol, Inc. has several U.S. and foreign patent applications pending.


Senior Member
United States, New Hampshire
A couple of quotes from the article-

Since 2018, Dr. Salerno treated patients diagnosed with COPD, Asthma, COVID-19, Long-COVID, and ME/CFS with Inspiritol. Inspiritol Inc. is seeking approval from the FDA to conduct human clinical trials on patients with COVID-19, Long-COVID and ME/CFS.

Dr. Salerno stated, "A hallmark of Inspiritol treated patients is a rapid increase of oxygen in their blood and decreases in fatigue and difficulty thinking, commonly referred to as 'brain fog'."
Dr. Liisa Selin, MD, Ph.D., Professor of Pathology and a specialist in infectious diseases and immunology with Anna Gil, Ph.D., both at UMass Chan Medical School have developed new methods to study biomarkers of chronic inflammatory diseases.

They discovered similarities in immune system responses of Long-COVID and ME/CFS patients, including CD8 T cell exhaustion, increased frequency of CD4+CD8+ T cells, and difficulty controlling persistent viral pathogens.

Dr. Selin said, "Our research findings could point to potential biomarkers, treatments and ways of tracking responses to therapies for Long-COVID and ME/CFS, methods that are immediately needed.

Our research indicates that individuals with Long-COVID and ME/CFS have biological abnormalities, including; oxidative stress imbalances, systemic inflammation and neuroinflammation."

Working with Dr. Salerno's patients, Dr. Selin and Dr. Gil ran these same biomarker tests on two with Long-COVID and one with ME/CFS and reported,

"We obtained dramatic improvement of these patients' symptoms associated with changes in their biomarkers without evidence of any significant side effects, including routine blood work, following continuous Inspiritol therapy from 2 to more than 5 months."
Last edited:
so its the delivery system? (they want to control?)

Why should NAC, glutathione....common supplements- be Trademarked or whatever we call this?